Characteristics of patients in MLL-10
Characteristic . | All . | KMT2A-g . | KMT2A-r . | ||
---|---|---|---|---|---|
LR (n = 15) . | IR (n = 19) . | HR (n = 56) . | IR + HR (n = 75) . | ||
No. (%) . | No. (%) . | No. . | No. . | No. (%) . | |
Sex | |||||
Male | 47 (52) | 10 (67) | 13 | 24 | 37 (49) |
Female | 43 (48) | 5 (33) | 6 | 32 | 38 (51) |
Age at diagnosis, days | |||||
0-89 | 22 (24) | 1 (7) | 0 | 21 | 21 (28) |
90-179 | 37 (41) | 2 (13) | 0 | 35 | 35 (47) |
180-365 | 31 (34) | 12 (80) | 19 | 0 | 19 (25) |
WBC × 109/L at diagnosis | |||||
<100 | 44 (49) | 12 (80) | 12 | 20 | 32 (43) |
100 to <300 | 19 (21) | 3 (20) | 2 | 14 | 16 (21) |
≥300 | 27 (30) | 0 (0) | 5 | 22 | 27 (36) |
Immunophenotype | |||||
B-lineage CD10– | 62 (69) | 1 (7) | 14 | 47 | 61 (81) |
B-lineage CD10+ | 28 (31) | 14 (93) | 5 | 9 | 14 (19) |
CNS involvement* | |||||
Positive (CNS-3) | 10 (11) | 0 (0) | 0 | 10 | 10 (13) |
Negative (CNS-1 or CNS-2) | 79 (88) | 15 (100) | 19 | 45 | 64 (85) |
Unknown | 1 (1) | 0 (0) | 0 | 1 | 1 (1) |
KMT2A status | |||||
Germline | 15 (17) | 15 (100) | 0 | 0 | — |
Rearranged | 75 (83) | — | 19 | 56 | 75 (100) |
t(4;11)/KMT2A-AFF1 | — | 11 | 28 | 39 (52) | |
t(9;11)/KMT2A-MLLT3 | — | 3 | 3 | 6 (8) | |
t(11;19)/KMT2A-MLLT1 | — | 1 | 14 | 15 (20) | |
Other KMT2A-r | — | 4 | 11 | 15 (20) | |
Prednisolone response | |||||
PGR | 60 (67) | 12 (80) | 17 | 31 | 48 (64) |
PPR | 30 (33) | 3 (20) | 2 | 25 | 27 (36) |
Characteristic . | All . | KMT2A-g . | KMT2A-r . | ||
---|---|---|---|---|---|
LR (n = 15) . | IR (n = 19) . | HR (n = 56) . | IR + HR (n = 75) . | ||
No. (%) . | No. (%) . | No. . | No. . | No. (%) . | |
Sex | |||||
Male | 47 (52) | 10 (67) | 13 | 24 | 37 (49) |
Female | 43 (48) | 5 (33) | 6 | 32 | 38 (51) |
Age at diagnosis, days | |||||
0-89 | 22 (24) | 1 (7) | 0 | 21 | 21 (28) |
90-179 | 37 (41) | 2 (13) | 0 | 35 | 35 (47) |
180-365 | 31 (34) | 12 (80) | 19 | 0 | 19 (25) |
WBC × 109/L at diagnosis | |||||
<100 | 44 (49) | 12 (80) | 12 | 20 | 32 (43) |
100 to <300 | 19 (21) | 3 (20) | 2 | 14 | 16 (21) |
≥300 | 27 (30) | 0 (0) | 5 | 22 | 27 (36) |
Immunophenotype | |||||
B-lineage CD10– | 62 (69) | 1 (7) | 14 | 47 | 61 (81) |
B-lineage CD10+ | 28 (31) | 14 (93) | 5 | 9 | 14 (19) |
CNS involvement* | |||||
Positive (CNS-3) | 10 (11) | 0 (0) | 0 | 10 | 10 (13) |
Negative (CNS-1 or CNS-2) | 79 (88) | 15 (100) | 19 | 45 | 64 (85) |
Unknown | 1 (1) | 0 (0) | 0 | 1 | 1 (1) |
KMT2A status | |||||
Germline | 15 (17) | 15 (100) | 0 | 0 | — |
Rearranged | 75 (83) | — | 19 | 56 | 75 (100) |
t(4;11)/KMT2A-AFF1 | — | 11 | 28 | 39 (52) | |
t(9;11)/KMT2A-MLLT3 | — | 3 | 3 | 6 (8) | |
t(11;19)/KMT2A-MLLT1 | — | 1 | 14 | 15 (20) | |
Other KMT2A-r | — | 4 | 11 | 15 (20) | |
Prednisolone response | |||||
PGR | 60 (67) | 12 (80) | 17 | 31 | 48 (64) |
PPR | 30 (33) | 3 (20) | 2 | 25 | 27 (36) |
PGR, prednisolone good responder; PPR, prednisolone poor responder.
CNS-3, ≥5 WBCs per μL in cerebral spinal fluid (CSF) with blasts; CNS-2, <5 WBCs per μL in CSF with blasts; CNS-1, absence of blasts in CSF regardless of the number of WBCs.